Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Teva
Chubb
Express Scripts
Cerilliant
Johnson and Johnson
Cantor Fitzgerald
Covington
QuintilesIMS
Colorcon

Generated: February 20, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021526

« Back to Dashboard

NDA 021526 describes RANEXA, which is a drug marketed by Gilead and is included in one NDA. It is available from four suppliers. There are ten patents protecting this drug. Additional details are available on the RANEXA profile page.

The generic ingredient in RANEXA is ranolazine. There are eighteen drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the ranolazine profile page.
Summary for 021526
Tradename:RANEXA
Applicant:Gilead
Ingredient:ranolazine
Patents:10
Therapeutic Class:Cardiovascular Agents
Formulation / Manufacturing:see details
Suppliers and Packaging for NDA: 021526
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
RANEXA ranolazine TABLET, EXTENDED RELEASE;ORAL 021526 NDA Aphena Pharma Solutions - Tennessee, LLC 43353-880 N 43353-880-83
RANEXA ranolazine TABLET, EXTENDED RELEASE;ORAL 021526 NDA Cardinal Health 55154-4427 E 55154-4427-0

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrength1GM
Approval Date:Feb 12, 2007TE:RLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:May 27, 2019Product Flag?Substance Flag?Delist Request?
Patented Use:TREATING CHRONIC ANGINA BY ADMINISTERING AN EXTENDED RELEASE FORM OF RANOLAZINE
Patent:➤ Try a Free TrialPatent Expiration:May 27, 2019Product Flag?YSubstance Flag?Delist Request?Y
Patent:➤ Try a Free TrialPatent Expiration:May 27, 2019Product Flag?Substance Flag?Delist Request?
Patented Use:TREATING CHRONIC ANGINA BY ADMINISTERING AN EXTENDED RELEASE FORM OF RANOLAZINE

Expired US Patents for NDA 021526

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Gilead RANEXA ranolazine TABLET, EXTENDED RELEASE;ORAL 021526-001 Feb 12, 2007 ➤ Try a Free Trial ➤ Try a Free Trial
Gilead RANEXA ranolazine TABLET, EXTENDED RELEASE;ORAL 021526-002 Jan 27, 2006 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Baxter
Medtronic
Citi
Cipla
Fish and Richardson
Dow
McKinsey
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot